Noven Pharmaceuticals (NOVN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Noven Pharmaceuticals (NOVN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Frederick Langford who wrote (37)	3/9/1999 10:27:00 AM
From: zizzerzazzer	Read Replies (1) of 66

NOVN beats consensus estimate by $0.05. Reported 4Q 1998 EPS of $0.03 vs consensus estimated loss of -$0.02 and vs -$0.23 loss in 4Q 1997. Anaylyst (Fahnestock) has reported that prescription trends for Compipatch are very positive. Second generation Vivelle patch will begin to be sold in mid-1999. The following is a quote from user of Combipatch posted in message #806 on the Yahoo board: <<I have been on the Combipatch for about three weeks now and it is GREAT. No hot flashes and the patch sticks without any irritation. I saw a different Doc in this group and he said he never gave his patients hrt patches before but now he is telling his patients to use Combipatch.!!!!!!!>> Good chance of continued positive earnings surprises throughout 1999.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next